Stavudine

Stavudine

Form: Capsules & Oral Solution

Strength: Cap: 15 mg, 20 mg, 30 mg, 40 mg; Oral Solution:1 mg/mL

Reference Brands: Zerit®(EU& US),Stavir®

Category: Anti Viral

Stavudine Capsules (d4T), sold under brand names like Zerit® and Stavir®, are NRTI antiretroviral drugs used in combination therapy for HIV-1 infection. Though phased out in many regions due to toxicity concerns, Stavudine remains accessible in certain countries under legacy protocols. Available in 15 mg to 40 mg strengths, these capsules are supplied by multiple WHO-GMP manufacturers. Through PharmaB2B platforms, global buyers can source quality-assured Stavudine for public health programs, tenders, and NGO-driven supply chains. Cost-effective and reliable for legacy care, Stavudine supports continued access to HIV treatment where alternative therapies may be limited.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.